Nägele, V., Kratzer, A., Zugmaier, G., Holland, C., Hijazi, Y., Topp, M. S., . . . Klinger, M. (2017). Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL. Exp Hematol Oncol.
Citação norma ChicagoNägele, Virginie, et al. "Changes in Clinical Laboratory Parameters and Pharmacodynamic Markers in Response to Blinatumomab Treatment of Patients With Relapsed/refractory ALL." Exp Hematol Oncol 2017.
Citação norma MLANägele, Virginie, et al. "Changes in Clinical Laboratory Parameters and Pharmacodynamic Markers in Response to Blinatumomab Treatment of Patients With Relapsed/refractory ALL." Exp Hematol Oncol 2017.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.